Fig. 3From: Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trialThe proportion of patients maintaining virologic response (HBV DNA <60 IU/mL) in the study. Patients who discontinued the study prior to week 48 for any reason were considered failures in virologic response at the time of discontinuationBack to article page